Evidence map›Paper›PMID 28439468›Full record

ArticlePeerJ2017

A link between central kynurenine metabolism and bone strength in rats with chronic kidney disease.

Bartlomiej Kalaska, Krystyna Pawlak, Ewa Oksztulska-Kolanek, Tomasz Domaniewski, Beata Znorko, Malgorzata Karbowska, Aleksandra Citkowska, Joanna Rogalska, Alicja Roszczenko, Malgorzata M Brzoska and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PeerJ, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.5field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Review
  3. The Role of Tryptophan Metabolites in Musculoskeletal Stem Cell Aging.International journal of molecular sciences · 2020
    Review
  4. Article
  5. Article
  6. Kynurenine Pathway in Chronic Kidney Disease: What's Old, What's New, and What's Next?International journal of tryptophan research : IJTR · 2020
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Bartlomiej KalaskaDepartment of Pharmacodynamics, Medical University of Bialystok, Bialystok, Poland.
Krystyna PawlakDepartment of Monitored Pharmacotherapy, Medical University of Bialystok, Bialystok, Poland.
Ewa Oksztulska-KolanekDepartment of Monitored Pharmacotherapy, Medical University of Bialystok, Bialystok, Poland.
Tomasz DomaniewskiDepartment of Monitored Pharmacotherapy, Medical University of Bialystok, Bialystok, Poland.
Beata ZnorkoDepartment of Monitored Pharmacotherapy, Medical University of Bialystok, Bialystok, Poland.
Malgorzata KarbowskaDepartment of Pharmacodynamics, Medical University of Bialystok, Bialystok, Poland.
Aleksandra CitkowskaDepartment of Pharmacodynamics, Medical University of Bialystok, Bialystok, Poland.
Joanna RogalskaDepartment of Toxicology, Medical University of Bialystok, Bialystok, Poland.
Alicja RoszczenkoDepartment of Toxicology, Medical University of Bialystok, Bialystok, Poland.
Malgorzata M BrzoskaDepartment of Toxicology, Medical University of Bialystok, Bialystok, Poland.
Dariusz PawlakDepartment of Pharmacodynamics, Medical University of Bialystok, Bialystok, Poland.
Medical University of Białystok · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDisturbances in mineral and bone metabolism represent one of the most complex complications of chronic kidney disease (CKD). Serotonin, a monoamine synthesized from tryptophan, may play a potential role in bone metabolism. Brain-derived serotonin exerts a positive effect on the bone structure by limiting bone resorption and enhancing bone formation. Tryptophan is the precursor not only to the serotonin but also and primarily to kynurenine metabolites. The ultimate aim of the present study was to determine the association between central kynurenine metabolism and biomechanical as well as geometrical properties of bone in the experimental model of the early stage of CKD.

methodsThirty-three Wistar rats were randomly divided into two groups (sham-operated and subtotal nephrectomized animals). Three months after surgery, serum samples were obtained for the determination of biochemical parameters, bone turnover biomarkers, and kynurenine pathway metabolites; tibias were collected for bone biomechanical, bone geometrical, and bone mass density analysis; brains were removed and divided into five regions for the determination of kynurenine pathway metabolites.

resultsSubtotal nephrectomized rats presented higher serum concentrations of creatinine, urea nitrogen, and parathyroid hormone, and developed hypocalcemia. Several biomechanical and geometrical parameters were significantly elevated in rats with experimentally induced CKD. Subtotal nephrectomized rats presented significantly higher kynurenine concentrations and kynurenine/tryptophan ratio and significantly lower tryptophan levels in all studied parts of the brain. Kynurenine in the frontal cortex and tryptophan in the hypothalamus and striatum correlated positively with the main parameters of bone biomechanics and bone geometry. DISCUSSION: In addition to the complex mineral, hormone, and metabolite changes, intensified central kynurenine turnover may play an important role in the development of bone changes in the course of CKD.

Indexed as

Bone disordersBrainChronic kidney diseaseKynurenine pathway

Identifiers

PMID28439468
PMCPMC5401623
OpenAlexW2606195822

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.